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Introduction: Molecular genetic analyses of lung adenocarcinoma 
have recently become standard of care for treatment selection. The 
Lung Cancer Mutation Consortium was formed to enable collabor-
ative multi-institutional analyses of 10 potential oncogenic driver 
mutations. Technical aspects of testing and clinicopathologic cor-
relations are presented.
Methods: Mutation testing in at least one of the eight genes (epidermal 
growth factor receptor [EGFR], KRAS, ERBB2, AKT1, BRAF, MEK1, 
NRAS, and PIK3CA) using SNaPshot, mass spectrometry, Sanger 
sequencing+/− peptide nucleic acid and/or sizing assays, along with ana-
plastic lymphoma kinase (ALK) and/or MET fluorescence in situ hybrid-
ization, were performed in six labs on 1007 patients from 14 institutions.
Results: In all, 1007 specimens had mutation analysis performed, and 
733 specimens had all 10 genes analyzed. Mutation identification rates 
did not vary by analytic method. Biopsy and cytology specimens were 
inadequate for testing in 26% and 35% of cases compared with 5% 
of surgical specimens. Among the 1007 cases with mutation analysis 
performed, EGFR, KRAS, ALK, and ERBB2 alterations were detected 
in 22%, 25%, 8.5%, and 2.4% of cases, respectively. EGFR mutations 
were highly associated with female sex, Asian race, and never-smok-
ing status; and less strongly associated with stage IV disease, presence 
of bone metastases, and absence of adrenal metastases. ALK rearrange-
ments were strongly associated with never-smoking status and more 
weakly associated with presence of liver metastases. ERBB2 mutations 
were strongly associated with Asian race and never-smoking status. 
Two mutations were seen in 2.7% of samples, all but one of which 
involved one or more of PIK3CA, ALK, or MET.
Conclusion: Multi-institutional molecular analysis across multiple 
platforms, sample types, and institutions can yield consistent results 
and novel clinicopathological observations.
Key Words: Lung adenocarcinoma, Mutation, FISH, Genotyping, 
LCMC.
(J Thorac Oncol. 2015;10: 768–777)
Molecular genetic testing is a central component of path-ological analysis for several types of cancers. Although 
results formally reported in the medical record must be generated 
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in laboratories subject to Clinical Laboratory Improvement 
Amendments (CLIA) certification, the degree of interlabora-
tory variation with regard to molecular pathology methods and 
results remains poorly characterized outside of laboratory pro-
ficiency testing and studies designed specifically to evaluate 
concordance. Molecular testing in patients with advanced lung 
cancer and other solid tumors presents unique challenges. The 
use of minimally invasive procedures to obtain tissue for diag-
nosis often limits available tumor material for molecular test-
ing. Variable preanalytic methodology introduces the potential 
for poor nucleic acid preservation in formalin-fixed, paraffin-
embedded tumor samples. Furthermore, the continuing identi-
fication of new driver mutations can lead to repetitive testing of 
the same sample exhausting the material available.
Molecular genetic testing became central to the clinical 
management of advanced lung adenocarcinoma (ACA) after 
the discovery of a strong association between activating epi-
dermal growth factor receptor (EGFR) mutations and clini-
cal response to targeted EGFR tyrosine kinase inhibitors in 
2004.1–3 This was followed by the identification of rearrange-
ments of the anaplastic lymphoma kinase (ALK) gene in lung 
ACA in 2007, which are in turn uniquely sensitive to treat-
ment with ALK kinase inhibitors.4,5 EGFR mutation analysis 
and ALK fluorescence in situ hybridization (FISH) are now 
guideline-recommended standard-of-care at the time of diag-
nosis for advanced lung ACA to inform the initial systemic 
treatment.6 Ongoing recognition of potentially targetable 
oncogenic drivers in lung ACA7 indicates a need for efficient 
multiplexed analyses. Indeed, many institutions in the United 
States and worldwide have implemented routine analyses of 
multiple genes in lung ACA.8–10 A growing number of com-
mercial and academic institutions are implementing next gen-
eration sequencing of large gene panels as a more efficient 
approach to molecular testing across multiple cancer types.11–13
The Lung Cancer Mutation Consortium (LCMC) was 
established in 2008 as a multi-institutional program inves-
tigating the frequency of selected oncogenic drivers in lung 
ACA and using the results to treat the enrolled subjects with 
targeted therapies, either as part of standard clinical care or 
on investigational protocols. Fourteen institutions participated 
in the LCMC and either performed testing locally or utilized 
another LCMC site. Analytical methods at testing sites were 
left up to each institution, as long as they met CLIA standards.
The primary results of the LCMC study have recently 
been reported.14 Here, we provide additional information on 
methods used at the different institutions, results of blinded 
proficiency testing, effects of sample type and testing platform 
on assay success and mutation detection rates, and validation 
of mutations identified in lung cancer specimens with more 
than one putative driver alteration. Further, we examine sample 
failure rates and present a correlation between the presence of 
oncogenic driver mutations and clinicopathologic findings.
MATERIALS AND METHODS
Patient Recruitment and Enrollment
Fourteen clinical sites participated in the LCMC 
(Supplemental Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A814). All participating sites 
obtained local Institutional Review Board approval for partici-
pation in this study. Patients with stage IV or recurrent lung 
ACA; Southwest Oncology Group performance status of 0, 1, 
or 2; expected survival of more than 6 months; and adequate 
tissue for molecular analyses were eligible for entry on this 
study. One thousand five hundred and forty-two patients were 
enrolled, and 1102 were deemed eligible. The most common 
reason for ineligibility was inadequate pathologic material to 
complete the multiplexed testing (n = 286 of 440 ineligible; 
65%). Epidemiologic and clinicopathologic data were col-
lected on these subjects, including age, sex, race, smoking 
history, stage at diagnosis, metastatic sites, and survival.14
Pathology Evaluation
Anatomic pathologists at each institution confirmed 
a diagnosis of lung adenocarcinoma, assessed tumor con-
tent, and determined specimen adequacy based on analytic 
sensitivity of their testing platform (Table 1). Samples were 
enriched for tumor content using manual microdissection. 
Central confirmation of lung ACA diagnosis was based on 
review of an hematoxylin and eosin-stained histology slide or 
a scanned image (Aperio, Vista, CA), by I.I.W., J.F., or W.A.F. 
At the time of central review, expert pathologists enumerated 
percentage of each histologic pattern, including lepidic, aci-
nar, papillary, micropapillary, solid, and variants (mucinous, 
colloid, fetal, and enteric, as appropriate), according to the 
current criteria.15
Among the 1102 eligible patients, 1015 were confirmed 
as ACA histology and 2 as adenosquamous carcinoma by cen-
tral pathology review. In 85 cases, slides were not provided 
for central review. Among cases with confirmed histology, at 
least one molecular assay was performed in 1007 cases. Small 
mutations were defined as single nucleotide variants and small 
insertion/deletion (indel) mutations. Testing for at least one 
small-mutation gene (eight genes, see below) was performed 
for 989 cases, ALK FISH testing was performed in 926 cases, 
and MET FISH testing in 833. The 10-marker panel including 
small mutation and FISH testing was completed in its entirety 
for 733 patients.
Mutational Analyses
The vast majority of the mutation analyses were per-
formed in six diagnostic laboratories, using methods sum-
marized in Table 1. The complete panel of small mutations 
consisted of four small indels and 93 point mutations occur-
ring in eight genes (AKT1, BRAF, EGFR, ERBB2, KRAS, 
MAP2K1, NRAS, and PIK3CA; Supplemental Table 2, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A814). Because of variability in testing platforms, not all 
mutations were evaluated at all sites, but every site tested at 
least half of the complete set of mutations.
Three different methodologies were used for genotyp-
ing, and the analytic sensitivities for the major testing labo-
ratories (defined as those testing ≥ 4% of the total cases) are 
shown in Table 1. The methods for all mutational analyses 
have been previously published.15–17 Briefly, SNaPshot (Life 
Technologies, Grand Island, NY) is a multiplex polymerase 
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chain reaction (PCR) assay followed by single-base primer 
extension. Sequenom MassARRAY (Sequenom, San Diego, 
CA) is a multiplex PCR assay followed by single base exten-
sion sequencing and matrix-assisted laser desorption/ioniza-
tion-time of flight mass spectrometry. PCR followed by sizing 
assay for EGFR exons 19 and 20 and ERBB2 exon 20 using 
fluorescently labeled primers and capillary electrophoresis 
was used to detect the indel mutations for both SNaPshot and 
Sequenom.17 For bidirectional Sanger sequencing, assay sensi-
tivity was enhanced using peptide nucleic acid (PNA) clamps 
to suppress amplification of the wild-type allele at mutation 
hotspots in EGFR, KRAS, and BRAF. PNA clamp design for 
EGFR and KRAS has been previously described18,19; clamp 
design for BRAF is available upon request. Positive small 
mutation findings were confirmed by repeat testing in most 
cases, DNA quantity permitting, for all three methodologies.
Fluorescence In Situ Hybridization Analyses
ALK FISH assays were performed with the analyte spe-
cific reagent LSI ALK Dual Color, Break-Apart Rearrangement 
Probe or the IVD Vysis ALK Break Apart FISH Probe Kit 
(Abbott Molecular). The MET FISH assays were performed 
with laboratory-developed reagents (DNA insert encompass-
ing MET from the RP 11-95I20 BAC clone and a centromere 7 
control probe) or with commercial reagents (MET [Texas Red]/
CEP7 [D7Z1] Green from Cytocell; MET [ZyGreen]/CEP7 
[ZyOrange] from ZytoVision; Vysis MET SpectrumRed/
CEP 7 [D7Z1] SpectrumGreen from Abbott Molecular; or 
Poseidon Repeat Free c-MET [7q31] PlatinumBright550/SE 7 
PlatinumBright495 from Kreatech). All probe sets were vali-
dated to identify copy number changes in MET on 7q31.2 and 
used a centromere 7 control probe to define the relative copy 
number alteration.
FISH reagents were validated internally at each of the 
six diagnostic laboratories that performed testing as part of the 
LCMC (Supplemental Table 1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A814). Hybridization followed 
standard procedures and signals were evaluated in at least 50 
tumor nuclei per specimen; samples containing fewer than 50 
tumor nuclei were considered inadequate. ALK rearrangement 
was defined by split 3′ALK–5′ALK signals (separated by a gap 
≥2 times the signal diameter) or an isolated 3’ALK signal (no 
5’ALK signal) in ≥15% of tumor cells.5 MET amplification 
was considered to be present when the MET/centromere 7 
ratio was more than 2.2.
Interinstitutional Assay Validation 
and Proficiency Testing
The validation cohort included mutant cell lines and 
de-identified clinical specimens of known genotype col-
lected at one site; extracted DNA was shared with participat-
ing laboratories (Supplemental Table 3, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A814). Mutation assays 
for which no corresponding samples suitable for cross-vali-
dation between laboratories were available were validated 
independently by each participating laboratory, using syn-
thetic oligonucleotides harboring the mutation of interest. 
Control samples for FISH assay validation consisted of a 
panel of MET-amplified and EML4-ALK fusion positive lung 
ACA, provided to each participating laboratory by a single 
site (Supplemental Table 3, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A814).
Proficiency assessment was performed by individual 
LCMC laboratories on an ongoing basis, in compliance 
with CLIA guidelines. In addition, we designed a profi-
ciency testing protocol that was carried out at the onset of 
the study, to serve as extra measure of quality assurance 
and to internally document the reliability and accuracy of 
the tests performed by participating laboratories. One site 
provided five blinded samples derived from archival tumor 
containing a minimum of 200 ng of DNA to the other cen-
ters and evaluated their mutation results. FISH proficiency 
assessment consisted of the blinded evaluation of four lung 
adenocarcinoma surgical cases, two each for MET gene 
amplification and ALK gene rearrangement. One unstained 
5-μm section and paired hematoxylin and eosin-stained 
slide per FISH assay was submitted to participating labora-
tories for analysis.
Confirmation of Cases with Multiple Alterations
Confirmation of FISH results in cases with multiple 
driver alterations was performed when adequate tissue was 
available. Confirmation was carried out by repeating the 
FISH assay and when possible by using an orthogonal tech-
nique. ALK immunohistochemistry using clone 5A4 (Abcam, 
Cambridge, MA) was applied in cases with a mutation and 
TABLE 1.  Analytic Methods and Sensitivity Across Six Major Testing Sites
Number of Sites Platform Analytic Sensitivity (%) Minimum Accepted Tumor Cellularityb (%)
4 SNapShot 5–10 10–20a
PCR-sizing 5–10 10–20
1 Sequenom 5–10 25
PCR-sizing 5–10 25
1 Sanger 25 50
Sanger with PNA* 5 10
These six sites were responsible for more than 90% of mutation testing. A single site (not included here) produced only 1% of the overall results and utilized a different methodology 
(pyrosequencing) and thus is not included in these cross-platform analyses.
aPNA clamps were used to enhance sensitivity of mutation detection in EGFR, KRAS, and BRAF genes.
bManual microdissection to isolate tumor-rich areas for DNA extraction was performed at all sites.
PCR, polymerase chain reaction; PNA, peptide nucleic acid.
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ALK-rearrangement, as previously described.20 MET copy 
number was confirmed using dual color in situ hybridization 
(ISH) probes to the MET locus and CEN7 with dual color 
open probe software (Ventana Medical Systems, Tucson, AZ). 
Because dual ISH has been demonstrated to underestimate the 
probe to centromere ratio when compared with FISH,21 the 
cutoff for MET amplification was defined as a MET/centro-
mere 7 ratio of greater than 1.8 for this analysis.
Database Systems and Statistical Methods
Data were collected from participating institutions 
through entry into GeneInsight, a centralized web-based 
system.
Analyses evaluating efficiency of small-mutation test-
ing were institution-specific and represented as a ratio of 
total mutation calls to total number of mutations assessed 
on the relevant testing platform. Failure to complete all calls 
occurred due to technical failures plus incomplete testing for 
various reasons including sample insufficiency.
The Kruskal–Wallis test was utilized for group compar-
ison of continuous variables, and χ2 test was used for categori-
cal variables.
RESULTS
Subjects Studied and Overall Findings
The frequency of mutations identified in 733 completely 
tested lung ACA is shown in Figure 1, summarizing the data 
from our earlier publication on the LCMC experience.14 Note 
that in Figure 1, cases with two mutations are represented 
only once, selecting the mutation that primarily dictated clini-
cal care in each patient. As a result, the frequencies of ALK, 
MET, and PIK3CA alterations appear lower in this figure. (See 
Table 2 for details on doubleton mutations.)
When considering the 1007 cases with any genotyp-
ing, and including mutations occurring in doubletons, KRAS 
and EGFR mutations were seen in 25% and 22% of samples, 
respectively, and ALK rearrangement was detected in 8.5% 
of cases. Mutations in ERBB2, BRAF, PIK3CA, NRAS, and 
MEK1 and MET amplification, were all seen at less than 3% 
frequency. AKT1 was mutated in a single case.
Effects of Assay Methodology and 
Specimen Type on Genetic Findings
To determine whether assay methodology had an influ-
ence on mutation detection, we assessed results according to 
method of analysis, irrespective of institution. Of 813 speci-
mens with any genotyping performed for which specimen 
type information was available; 289 were biopsies (36%); 134 
were cytology specimens, including effusions and fine needle 
aspirates (16%); and 390 were surgical resections, including 
primary tumor resections and resections of metastatic sites 
(48%). The small mutation completion rate was very high 
(≥98%) for all specimen types (Table 3), which likely reflects 
the effectiveness of pathology prescreening to exclude cases 
with inadequate material. Similarly, there was no significant 
difference in the frequency of detection of small mutations 
according to specimen type, with a positive call rate of 55% 
for biopsies, 56% for cytology specimens, and 56% for sur-
gical resections (p = 0.97; Table 3). KRAS and EGFR muta-
tions were somewhat more common in surgical resections and 
cytology specimens, respectively, but the differences were not 
statistically significant (Supplemental Table 4, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A814).
MET FISH testing was implemented later than other 
testing at some sites thereby limiting its overall completion 
rate. Thus, we focused on ALK FISH testing to assess FISH 
completion rates (Table 3). There was no significant difference 
in ALK FISH completion rates based on specimen type, with 
results returned on 91% of biopsies, 92% of cytology speci-
mens, and 95% of surgical resection specimens (p = 0.14). In 
addition, specimen type had no impact on the frequency of 
ALK positive findings (p = 0.73, Table 3).
Specimen Sufficiency
Anticipating specimen adequacy for molecular testing 
and clinical trial enrollment is one of the most challenging 
aspects of modern clinical oncology. Several sites screened 
trial candidates for sample sufficiency before patient enroll-
ment in the study, thereby reducing the screen fail rate among 
enrolled subjects. One of the limitations of our data capture 
strategy emerged at the time of data analysis, when it became 
clear that site-to-site variation in prescreening practices were 
likely affecting the fail rate at individual institutions. We did 
not anticipate this issue in advance, and there was no preset 
procedure for prescreening, and no obligation to capture and 
document patients who failed to meet study eligibility based on 
lack of adequate tissue. Therefore, to evaluate the percentage 
FIGURE 1.  Mutations identified in the LCMC cohort. A pie 
chart is shown in which the size of each slice is proportional 
to the mutation frequency in the full genotyping set of 733 
patients. Cases with two mutations are represented only once 
based on the mutation that primarily dictated clinical care 
in each patient. As a result, the frequencies of ALK, MET, and 
PIK3CA alterations appear lower in this figure. (See Table 2 
for details.) Frequencies presented here also differ slightly 
for some genes in comparison with frequencies for the any-
genotyping group (n = 1007). See details of the full-geno-
typing versus any-genotyping cohorts and a comprehensive 
breakdown of all mutations identified in our original article 
on the LCMC experience, Ref. 14.
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of samples that were not sufficient for these molecular assays, 
and eliminate site-to-site variation, we focused our analysis 
on the site with highest mutational testing volume. Of the 470 
specimens of known specimen type submitted for testing at 
this site, 72 (15%) were rejected on the basis of insufficient 
tumor or being unsuitable for analysis (e.g., decalcification). 
Surgical resection specimens were significantly less likely to 
fail pathology screening (5% failure rate) when compared 
with biopsies and cytology specimens (26% and 35%, respec-
tively, p < 0.001, Table 4). We acknowledge that these fail-
ure rates may be an underestimate because candidate patients 
whose tumor specimens were likely to be insufficient at the 
time of consideration for this trial may not have been enrolled.
Proficiency Testing
A project-specific proficiency testing protocol per-
formed at the beginning of the study evaluated five specimens 
for mutation and four specimens for FISH analyses. Eight of 
nine proficiency samples were correctly scored by the par-
ticipating laboratories (Supplemental Table 5, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A814). One of 
the mutation samples (DNA 36) yielded unexpected results, 
with different labs reporting distinct mutations or a technical 
failure. It is possible that the integrity of this nucleic acid was 
compromised during processing or shipment, and the sample 
was classified as an ungraded challenge because of the lack of 
consensus among testing sites. One site that utilized Sanger 
sequencing with PNAs was unable to participate because the 
methodology required more sample material than provided for 
proficiency testing. For the duration of the study, all sites were 
engaged in proficiency assessment with blinded samples on a 
regular basis in compliance with CLIA/College of American 
Pathologists recommendations.
Analysis of Cases with Multiple Alterations
Twenty-seven cases (2.7% of 1007 samples with any 
genotyping) had multiple oncogenic driver mutations identi-
fied, including 14 with two small mutations and 13 with either 
a small mutation and ALK rearrangement (four); a small 
mutation and MET amplification (seven); or concurrent ALK 
rearrangement and MET amplification (two). Of 14 cases with 
two small mutations, 13 (92%) had a PIK3CA mutation in 
addition to another mutation, including nine with EGFR, two 
with BRAF, one with KRAS, and one1 with MEK1 mutation. 
One case had EGFR ex19del and AKT1 c.49G>A (p.E17K) 
mutations. All of these small mutation findings were validated 
by repeat analysis at the time of detection.
The 13 cases that had two mutations including a 
positive FISH result are presented in Table 2. MET amplifi-
cation co-occurred nine times with a variety of other altera-
tions including ALK rearrangement (two cases) and EGFR 
(2 cases), ERBB2 (1 case), and KRAS (4 cases) mutations. 
Replicate FISH testing and/or bright field ISH was performed 
in seven of these nine cases, and all were validated (including 
four by ISH). In the two cases with both MET amplification 
and ALK rearrangement, remaining tissue was insufficient for 
confirmation. ALK rearrangement was identified with con-
current small mutations in four cases, three with EGFR muta-
tions, and one with BRAF mutation. In two cases, follow-up 
testing, including using ALK immunohistochemistry and 
repeat FISH, failed to confirm a functional ALK rearrange-
ment (previously reported21). In one case, an EGFR mutation 
was confirmed but insufficient tissue remained to confirm the 
ALK rearrangement. This patient has not responded to either 
EGFR or ALK inhibitor treatment. In another case with con-
firmed ALK and EGFR alterations, follow-up information 
was not available.
TABLE 2.  Doubleton Molecular Alterations: Dual FISH or FISH-Mutation
Doubleton 
Case # Alteration #1 Alteration #2
Confirmed, Same 
Technique
Confirmed, Orthologous 
Technique Comments
1 ALK MET ND ND Insufficient tissue remaining
2 ALK MET ND ND Insufficient tissue remaining
3 ALK EGFR c.2582T>A ALK-ND, EGFR-Yes ND Patient experienced minimal response to 
sequential erlotinib and crizotinib therapies
4 ALK EGFR c.2573T>G ALK-No, EGFR-Yes No ALK IHC negative. Repeat ALK FISH showed 
atypical rearrangement, considered negative. 
Patient responded to erlotinib21
5 ALK EGFR ex19del Yes ND No follow-up data available
6 ALK BRAF c.1799T>A ALK-No, BRAF-Yes No ALK IHC negative. Repeat ALK FISH negative. 
Patient failed to respond to crizotinib21
7 EGFR ex19del MET Yes ND MET dual ISH was a technical failure
8 EGFR c.2573T>G MET Yes ND Insufficient tissue available for orthogonal testing
9 HER2 ex20ins MET Yes Yes MET dual ISH positive
10 KRAS c.35G>C MET Yes Yes MET dual ISH positive
11 KRAS c.35G>T MET Yes ND No tissue available for orthogonal testing
12 KRAS c.34G>T MET Yes Yes MET dual ISH positive
13 KRAS c.34G>T MET Yes Yes MET dual ISH positive
ND, not done; LCMC, Lung Cancer Mutation Consortium; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; ISH, in situ hybridization; EGFR, 
epidermal growth factor receptor.
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Clinicopathological Associations 
with Specific Mutations
The prevalence of any small mutation in this cohort was 
higher in females, those of Asian race, and never-smokers (all 
p ≤ 0.014, Fig. 2, Supplemental Table 6, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A815). There was no 
association between presence of any mutation and age or stage 
at diagnosis.
Multiple individual gene mutations showed signifi-
cant associations with clinicopathologic features (Fig. 2, 
Supplemental Table 6, Supplemental Digital Content 2, http://
links.lww.com/JTO/A815), many of which were expected 
(6). EGFR mutation was significantly associated with female 
gender, Asian race, never-smoking status, stage IV disease at 
diagnosis, the presence of bone metastases, and absence of 
adrenal metastases (all p ≤ 0.03). In contrast, KRAS mutation 
correlated with smoking (p < 0.001), older age at diagnosis (p 
< 0.001), lower frequency of bone metastases (p = 0.007), and 
white race (p = 0.006). ERBB2 mutations were significantly 
associated with a never-smoker status (p < 0.001) and Asian 
race (p = 0.015). ALK rearrangement was associated with a 
lower age at diagnosis (p < 0.001), never-smoker status (p < 
0.001), and liver metastases (p = 0.028). BRAF mutations and 
MET amplification were not associated with age, smoking his-
tory, stage at diagnosis, race, or metastatic pattern.
Approximately one-third of the specimens in the over-
all cohort were surgical resections. In this subgroup, we 
examined associations between histologic subtype22 and 
mutation. (Supplemental Table 7, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A814). We found no 
significant association between predominant histologic sub-
type and mutation, but there was a trend toward increased 
EGFR mutation frequency in acinar versus solid-predomi-
nant tumors (50 of 199, 25% vs. 23 of 165, 14%; p = 0.05), 
those two being the most common subtypes in the surgically 
resected subgroup. When considering median percentage 
TABLE 3.  Genotyping Efficiency and Positive Call Rate Per Specimen Type
Subsets Biopsy Cytology Surgical P Value
Specimens tested at all LCMC sites
Any small genotyping and known specimen type (n = 813) n = 289 n = 134 n = 390
Small-mutation genotyping efficiency (mean call rate 
across cases) 98% 99% 98% 0.04
Small-mutation positive call rate (proportion of cases 
detected with any small mutation) 55% (159) 56% (75) 56% (218) 0.97
Any genotyping and known specimen type (n = 855) n = 306 n = 145 n = 404
ALK FISH genotyping efficiency (proportion of cases with 
successful ALK testing) 91% (279) 92% (133) 95% (383) 0.14
ALK FISH genotyping and known specimen type (n = 795) n = 279 n = 133 n = 383
ALK FISH positive call rate (proportion of cases detected with ALK 
rearrangement) 10% (27) 8% (10) 8% (32) 0.73
Specimens tested at single LCMC site with plurality of testing
Any small genotyping and known specimen type (n = 360) n = 85 n = 33 n = 242
Small-mutation genotyping efficiency (mean call rate across cases) 96% 100% 99% 0.49
Small-mutation positive call rate (proportion of cases detected with 
any small mutation) 53% (45) 45% (15) 56% (136) 0.48
Any genotyping and known specimen type (n = 398) n = 100 n = 43 n = 255
ALK FISH genotyping efficiency (proportion of cases with successful 
ALK testing) 100% (100) 93% (40) 96% (245) 0.06
ALK FISH genotyping and known specimen type (n = 385) n = 100 n = 40 n = 245
ALK FISH positive call rate (proportion of cases 
detected with ALK rearrangement) 13% (13) 15% (6) 8% (20) 0.22
Specimens of unspecified type were not included in this analysis.
LCMC, Lung Cancer Mutation Consortium; ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization.
TABLE 4.  Specimen Sufficiency According to Type of Specimen, in 470 Specimens of Known Type, Tested at a Single LCMC 
Site with Plurality of Testing
Screen Failure for Insufficient 
Material Biopsy (n = 136) Cytology (n = 66) Surgical (n = 268) P Value
No 74% (100) 65% (43) 95% (255) <0.001
Yes 26% (36) 35% (23) 5% (13)
LCMC, Lung Cancer Mutation Consortium.
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of each subtype within a single specimen, none of lepidic, 
micropapillary, or papillary subtypes showed significant 
association with EGFR mutation status (Wilcoxon rank-sum 
test). However, a higher median percentage of acinar sub-
type within a specimen was associated with EGFR-positive 
status (median 95% acinar in EGFR-mutant; median 30% 
acinar in EGFR wild type; p = 0.008), whereas higher per-
centage of solid subtype was associated with EGFR-negative 
status (median 10% solid in EGFR wild type; median 0% 
solid in EGFR-mutant; p = 0.005).
FIGURE 2.  Demographic and prognostic associations with any and individual specific mutations. Statistically significant and 
other notable associations are shown in the form of bar graphs for several mutation types. “Any” refers to any identified muta-
tion. KRAS, EGFR, and ERBB2 consist of all point mutations occurring in those genes; ALK refers to translocations involving ALK, 
and MET refers to amplification of the MET locus, identified by FISH. More detailed demographic and prognostic association 
data are provided in Supplemental Table 7 (Supplemental Digital Content 1, http://links.lww.com/JTO/A814).
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DISCUSSION
This study demonstrates that collaborative efforts to 
share protocols and technology between laboratories facili-
tate comprehensive, multi-institutional tumor mutational 
profiling. Despite the diversity of analytic approaches 
employed (Table 1), our results show no appreciable evi-
dence of interlaboratory or interplatform variability in muta-
tion detection.
Specimen adequacy is a significant clinical issue in 
lung cancers because minimally invasive diagnostic proce-
dures are common. In this study, 1542 patients were enrolled, 
and only 1102 (71%) were deemed eligible. The majority of 
ineligible subjects were because of inadequate pathologic 
material. Iterative testing often requires recutting/resurfac-
ing (and associated “wasting”) of the tissue block, thus for 
many patients, tumor cells in the material were exhausted by 
the time all assays were implemented and often before analy-
sis by routine diagnostic methodology. As a result, only 733 
patients had complete genotyping performed, representing 
48% of the starting 1542 subjects enrolled. These observa-
tions highlight the challenges of implementing new and labor-
intensive molecular testing across multiple institutions and the 
need for careful planning in advance for tissue optimization. 
Indeed, our experience during the course of this study led 
many LCMC institutions to modify their tissue handling and 
diagnostic workup protocols, including modifying pathology 
requisitions to flag biopsies for genomic studies, requesting 
up-front serial tissue sections to reserve for molecular testing, 
and limiting immunohistochemistry analyses.
Focusing on the single site with the largest testing 
volume, to eliminate the effect of site-to-site differences in 
screening approaches, we determined that 35% of cytology 
specimens and 26% of small biopsies were insufficient when 
compared with 5% of surgical resections. However, once a 
specimen was deemed adequate, the sample type did not influ-
ence performance, and minor differences between comple-
tion rates were felt not to be clinically significant (Table 3). 
Despite recently published findings from College of American 
Pathologists demonstrating poor interlaboratory precision in 
determining tumor percentage based on review of an hema-
toxylin and eosin slide,23 our findings suggest that the pathol-
ogy prescreen to assess tumor percentage works well as a 
predictor of success of mutation analyses.
Although the frequencies of mutation seen here (Fig. 1) 
are similar to previous publications,24–27 they are somewhat 
higher overall, likely because of referral bias to the tertiary 
cancer centers making up the LCMC and provider enrollment 
of patients who were thought more likely to harbor targetable 
oncogenic mutation based on clinical and demographic fea-
tures. This phenomenon is reflected in the unusually high 
frequency of women versus men (60% vs. 40%) and never-
smoker and former-smoker vs. current smokers (34%, 59%, 
and 7%, respectively) in this cohort.
Consistent with prior reports,28 we found that most onco-
genic driver mutations occur in a mutually exclusive fashion. 
However, we identified 2.7% of cases with two or more putative 
driver alterations. PIK3CA mutations were the mutation type 
most often seen in combination with other alterations. PIK3CA 
mutations are seen in many cancer types and cause activation 
of both AKT and mammalian target of rapamycin, with myr-
iad downstream effects.29 The co-occurrence of mutations in 
PIK3CA and EGFR, and PIK3CA and KRAS, in lung adenocar-
cinoma is well established.27 Both in vitro studies and analysis of 
relapse biopsies suggest that PIK3CA activating mutations may 
confer resistance to gefitinib and erlotinib in EGFR-mutant lung 
adenocarcinoma.29,30 However, the clinical significance of these 
co-mutations at the time of primary diagnosis remains unclear.
The literature on co-occurrence of ALK rearrangement 
and other oncogenic driver mutations suggests that this is a 
rare event with unclear implications for therapy. A recently 
published large series of 1683 lung ACA tested for EGFR, 
KRAS, and ALK demonstrated that these were mutually exclu-
sive alterations.28 However, other reports suggest that com-
bined ALK rearrangement and EGFR and/or KRAS mutations 
may occur de novo31,32 and in postcrizotinib treated patients,33 
raising the possibility that combined ALK and EGFR block-
ade may be effective in a rare subset of lung ACA patients. 
We initially identified four cases with an ALK rearrangement 
combined with another driver mutation. Two proved to be 
false positives related to apparent poor tissue preservation in 
one case and an atypical FISH result in another; these false-
positive cases came to light as a result of negative ALK immu-
nohistochemistry.20 Since the initiation of the LCMC study, 
many advances have been made with regard to the implemen-
tation of IHC as a screening tool for high ALK expression in 
`. Although it was not widely available and hence not widely 
used during this study, the ALK IHC screening approach has 
merit. These lung adenocarcinoma findings suggest that care-
ful confirmation of dual alterations in ALK and another onco-
gene is warranted to exclude a false-positive or nonfunctional 
FISH result and to ensure that patients receive proper therapy.
MET amplification is an established mechanism of drug 
resistance in patients receiving EGFR tyrosine kinase inhibi-
tors34 and may be an adverse prognostic indicator in untreated 
non–small-cell lung carcinoma.35 Our data suggest that MET 
amplification, although rare in untreated specimens, occurs in 
a variety of genomic contexts. However, the limited number 
of cases in this study with dual alterations precludes analysis 
of differential response and outcomes data. The introduction 
of more comprehensive genomic testing into routine practice 
should help to elucidate the significance of multiple mutations 
for therapy selection and patient outcome.
The large number of patient samples evaluated in this 
study allowed for extensive analysis of mutation and clini-
copathologic correlations. Our findings were largely consis-
tent with existing literature, lending support to our results. 
However, we do acknowledge that many statistical tests were 
performed, leading the possibility of false-positive findings. 
With this caveat, our findings reinforce the known associations 
of EGFR mutations with female sex, Asian race, and never-
smoking status;26,36 KRAS mutation with smoking history; and 
ALK rearrangement with younger age, never-smoking status, 
and liver metastases.37 Indeed, nearly half (146 of 335, 44%) of 
never-smokers in this cohort had EGFR mutations. However, 
it is notable that over a third of patients with EGFR-mutated 
or ALK-rearranged tumors had some smoking history. Of 
current smokers, 6% had EGFR mutations and 6% had ALK 
rearrangements (Supplemental Table 6, Supplemental Digital 
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Content 2, http://links.lww.com/JTO/A815). Clear correla-
tions between tumor histologic pattern and mutation type are 
lacking, driven in part by variable recognition of defined sub-
types and by the morphologic complexity of lung adenocarci-
noma. After restricting the analysis to the cohort of surgically 
resected specimens and employing central, expert pathology 
review, we found EGFR mutations more strongly correlated 
with acinar than with solid subtype histology, although even 
in this latter group EGFR was mutated in 14% of cases.38,39 
These findings thus reinforce the widely adopted recommen-
dations that testing for these targetable alterations can be per-
formed on all lung adenocarcinoma patients, irrespective of 
patient demographics and tumor histologic subtype.6,40
This study is one of the largest of its kind to address the 
many challenges that arise in the course of molecular testing of 
solid tumors for therapeutic decision-making. It is reassuring 
that geographically diverse institutions serving a wide range of 
patient populations generate similar results using a variety of 
sample types and testing platforms, underscoring the ability of 
advanced molecular diagnostic laboratories to establish, vali-
date, and implement high-fidelity assays. However, our expe-
rience clearly highlights the drawbacks of sequential targeted 
genotyping in practice. Menu variation in multiplex genotyp-
ing assays means that individual institutions may offer incom-
plete coverage at certain targets, whereas Sanger sequencing 
provides more comprehensive coverage but at much lower 
analytic sensitivity and requires significantly more input DNA. 
FISH studies drive an increased need for tumor tissue, present-
ing a particular problem in lung adenocarcinoma where the 
number of gene fusions and copy number targets continue to 
grow. As a result, this iterative approach to mutational profiling 
appears unsustainable in the face of increasing numbers of tar-
getable alterations, and new approaches to testing are needed 
and are indeed in various stages of implementation nationally, 
such as next generation sequencing.
In summary, The LCMC demonstrates the feasibility 
of widespread implementation of mutational profiling in the 
clinical care of lung cancer patients. It lays the groundwork for 
future collaborative efforts that will be necessary to fully char-
acterize the mutational spectrum of lung cancers in light of the 
relative rarity of many of the newly recognized driver altera-
tions in this tumor type. As clinical oncology and molecular 
diagnostics embrace new technological platforms, this type of 
collaborative study is critical for validation of biomarkers and 
for facilitating identification of candidates for clinical trials.
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